Klaitman Vered, Almog Yaniv
Medical Intensive Care Unit, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Isr Med Assoc J. 2003 Jan;5(1):51-5.
Sepsis is an inflammatory syndrome caused by infection. Consequently, anti-inflammatory therapy in sepsis has been a subject of extensive research, and corticosteroids have long been used to treat severe infections. However, studies conducted in the 1980s failed to demonstrate any beneficial effects of high dose, short-term steroid therapy in sepsis and this therapy was therefore abandoned in the last decade. Recently, a new concept has emerged with more promising results--low dose, long-term hydrocortisone therapy- and this approach is now being evaluated in the treatment of septic shock. It is supported by the observation that many sepsis patients have relative adrenal insufficiency. Moreover, the anti-inflammatory effects of steroids and their ability to improve reactivity to catecholamines further contribute to their effects in sepsis. Large randomized clinical trials will be required to determine the exact role of corticosteroids in septic shock.
脓毒症是一种由感染引起的炎症综合征。因此,脓毒症的抗炎治疗一直是广泛研究的课题,长期以来皮质类固醇一直被用于治疗严重感染。然而,20世纪80年代进行的研究未能证明高剂量、短期类固醇治疗对脓毒症有任何有益效果,因此这种治疗方法在过去十年中被摒弃。最近,出现了一个更具前景的新概念——低剂量、长期氢化可的松治疗——目前正在对其治疗感染性休克的效果进行评估。许多脓毒症患者存在相对肾上腺功能不全这一观察结果为该方法提供了支持。此外,类固醇的抗炎作用及其改善对儿茶酚胺反应性的能力进一步促成了它们在脓毒症中的作用。需要进行大型随机临床试验来确定皮质类固醇在感染性休克中的确切作用。